Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedSep 07, 2025
DataAggregated Company Financials
Companies62
  • 7D-0.5%
  • 3M12.7%
  • 1Y-19.1%
  • YTD-9.3%

The Life Sciences industry has stayed flat over the last week. As for the longer term, the industry has declined 19% in the last year. Earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 07 Sep 2025US$576.5bUS$144.3bUS$14.6b29.9x39.6x4x
Tue, 05 Aug 2025US$552.8bUS$144.0bUS$13.0b32.1x42.4x3.8x
Thu, 03 Jul 2025US$541.5bUS$142.9bUS$9.1b36.3x59.3x3.8x
Sat, 31 May 2025US$507.5bUS$142.9bUS$9.2b32.4x54.9x3.6x
Mon, 28 Apr 2025US$519.3bUS$142.5bUS$10.0b37.5x52x3.6x
Wed, 26 Mar 2025US$601.4bUS$143.0bUS$9.9b38.9x60.8x4.2x
Fri, 21 Feb 2025US$620.2bUS$143.3bUS$9.6b38.4x64.4x4.3x
Sun, 19 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Tue, 17 Dec 2024US$666.2bUS$142.4bUS$10.2b45.5x65.2x4.7x
Thu, 14 Nov 2024US$683.4bUS$142.4bUS$10.3b45x66.4x4.8x
Sat, 12 Oct 2024US$724.1bUS$141.8bUS$8.5b37.7x85.3x5.1x
Mon, 09 Sep 2024US$731.3bUS$141.8bUS$8.5b37.5x86.1x5.2x
Wed, 07 Aug 2024US$722.7bUS$141.0bUS$11.3b36.7x64.2x5.1x
Fri, 05 Jul 2024US$662.1bUS$141.3bUS$12.2b38.5x54.4x4.7x
Sun, 02 Jun 2024US$702.1bUS$141.3bUS$12.4b38.2x56.5x5x
Tue, 30 Apr 2024US$709.6bUS$141.6bUS$12.7b39.6x55.8x5x
Thu, 28 Mar 2024US$742.5bUS$142.1bUS$12.8b43.9x58x5.2x
Sat, 24 Feb 2024US$729.7bUS$142.1bUS$12.4b43.7x58.8x5.1x
Mon, 22 Jan 2024US$691.1bUS$153.8bUS$14.2b35.9x48.8x4.5x
Wed, 20 Dec 2023US$697.4bUS$153.8bUS$14.2b37.4x49x4.5x
Fri, 17 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Sun, 15 Oct 2023US$629.3bUS$154.6bUS$11.2b33.2x56.2x4.1x
Tue, 12 Sep 2023US$690.0bUS$154.6bUS$11.2b32.2x61.6x4.5x
Thu, 10 Aug 2023US$729.3bUS$154.6bUS$11.3b30.2x64.6x4.7x
Sat, 08 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Mon, 05 Jun 2023US$683.1bUS$152.4bUS$12.5b29.1x54.6x4.5x
Wed, 03 May 2023US$696.7bUS$152.9bUS$9.4b28.7x73.9x4.6x
Fri, 31 Mar 2023US$715.3bUS$154.5bUS$10.8b26.5x66.3x4.6x
Sun, 26 Feb 2023US$712.1bUS$154.3bUS$11.0b30.1x65x4.6x
Tue, 24 Jan 2023US$784.3bUS$155.3bUS$8.5b31.9x92x5x
Thu, 22 Dec 2022US$747.2bUS$155.2bUS$8.8b28.7x85.1x4.8x
Sat, 19 Nov 2022US$749.5bUS$154.9bUS$8.8b27.8x84.7x4.8x
Mon, 17 Oct 2022US$693.0bUS$152.5bUS$17.0b23.6x40.7x4.5x
Wed, 14 Sep 2022US$811.0bUS$152.3bUS$17.3b30.9x46.8x5.3x
Price to Earnings Ratio

46.8x


Total Market Cap: US$811.0bTotal Earnings: US$17.3bTotal Revenue: US$152.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 39.6x which is lower than its 3-year average PE of 61.9x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 5.6% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.43%
Healthcare0.81%
Life Sciences-0.54%
Clinical Research and Equipment-0.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A Agilent TechnologiesUS$128.752.5%
+US$876.0m		-6.2%PE29.9x
TEM Tempus AIUS$79.625.0%
+US$653.2m		58.6%PS14.5x
MEDP Medpace HoldingsUS$486.982.4%
+US$322.2m		45.0%PE32.7x
STVN Stevanato GroupUS$24.155.0%
+US$311.2m		13.0%PE41.8x
WST West Pharmaceutical ServicesUS$250.731.5%
+US$271.8m		-15.6%PE37x

Latest News

FTRE
US$11.63
Fortrea Holdings
7D
18.1%
1Y
-42.1%

Global Demographic Trends Will Spur Clinical Advances

The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.
SHC
US$15.62
Sotera Health
7D
-4.6%
1Y
-0.2%
ICLR
US$174.88
ICON
7D
-1.7%
1Y
-42.2%
ILMN
US$98.93
Illumina
7D
-1.0%
1Y
-20.5%

Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks

Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.
WAT
US$306.32
Waters
7D
1.5%
1Y
-6.8%

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.
MEDP
US$486.98
Medpace Holdings
7D
2.4%
1Y
45.0%

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).
QGEN
US$47.55
Qiagen
7D
2.3%
1Y
3.9%

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
BRKR
US$30.83
Bruker
7D
-9.3%
1Y
-51.8%
IQV
US$187.68
IQVIA Holdings
7D
-1.6%
1Y
-22.8%
TEM
US$79.62
Tempus AI
7D
5.0%
1Y
58.6%
A
US$128.75
Agilent Technologies
7D
2.5%
1Y
-6.2%
AVTR
US$13.31
Avantor
7D
-1.2%
1Y
-47.9%
RVTY
US$86.64
Revvity
7D
-3.9%
1Y
-24.9%

Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest

Aug 14
Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest
DHR
US$200.21
Danaher
7D
-2.7%
1Y
-24.8%
STVN
US$24.15
Stevanato Group
7D
5.0%
1Y
13.0%

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
WST
US$250.73
West Pharmaceutical Services
7D
1.5%
1Y
-15.6%